SCHEDULE: Venrock Reduces Dianthus Therapeutics Stake to 3.1%
Beneficial Ownership Amendment
Venrock Healthcare Capital Partners and its affiliates have reduced their beneficial ownership in Dianthus Therapeutics, Inc. to 3.1% as of June 30, 2025.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Y. Koh (collectively, the "Reporting Persons") are filing this Amendment No. 2 to their Schedule 13G.
- The Reporting Persons collectively beneficially own 1,000,000 shares of Dianthus Therapeutics, Inc. Common Stock, $0.001 par value per share, as of June 30, 2025.
- This ownership represents 3.1% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 32,159,982 shares of Common Stock outstanding as of May 7, 2025, as reported in Dianthus Therapeutics' Quarterly Report on Form 10-Q filed on May 12, 2025.
- The Reporting Persons hold shared voting power and shared dispositive power over these 1,000,000 shares.
- This amendment indicates that the Reporting Persons' aggregate beneficial ownership has fallen to 5% or less of the class.
Sentiment
Score: 3
Explanation: The filing indicates a significant institutional investor group has reduced its stake in Dianthus Therapeutics to below 5%, which is typically viewed as a negative signal regarding investor confidence or future prospects.
Negatives
- A significant institutional investor group, Venrock Healthcare Capital Partners and its affiliates, has reduced its beneficial ownership in Dianthus Therapeutics, Inc. to 3.1%, falling below the 5% threshold.
- This reduction implies a decreased conviction or a strategic reallocation of capital by a notable healthcare-focused investment group.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May experience negative sentiment and potential downward pressure on share price due to the reduction in institutional ownership, which could be interpreted as a lack of confidence by a major investor.
Key Dates
| Date | Description |
|---|---|
| 05/07/2025 | Date as of which 32,159,982 shares of Dianthus Therapeutics' Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 05/12/2025 | Date Dianthus Therapeutics' Quarterly Report on Form 10-Q was filed with the SEC. |
| 06/30/2025 | Date of event which required the filing of this statement; beneficial ownership reported as of this date. |
| 08/14/2025 | Date the Schedule 13G Amendment No. 2 was signed. |
| 09/21/2023 | Date of previous Schedule 13G filing referenced for incorporated exhibits (Power of Attorney for Nimish Shah, Power of Attorney for Bong Koh, Joint Filing Agreement). |
Recommendation
holdThe filing indicates a reduction in beneficial ownership by a significant institutional investor group to 3.1%. While not an immediate sell signal, this reduction suggests a cautious stance from a major holder. Investors should hold and monitor for further developments or catalysts that could reverse this trend, as the reduced institutional backing may weigh on market sentiment.
Keywords
Dianthus Therapeutics, Venrock, Healthcare Capital Partners, Beneficial Ownership, Schedule 13G, Institutional Ownership, Common Stock, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.